Skip to main content
SpringerLink
Log in

Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

The aim of this study was to investigate the impact of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen and its metabolite. The CYP2C9 genotypes were determined with the use of polymerase chain reaction and restriction fragment and DNA sequencing analysis in 358 healthy Koreans. Among them, twenty individuals with CYP2C9*1/*1 (n = 12) or CYP2C9*1/*3 (n = 8) genotypes received a single 40 mg oral dose of flurbiprofen. The plasma concentrations of flurbiprofen and its metabolite, 4′-hydroxyflurbiprofen were measured by HPLC. AUCinf of flurbiprofen was significantly higher and its clearance was significantly lower in the CYP2C9*1/*3 individuals than in those with CYP2C9*1/*1. The AUC ratio of 4'-hydroxyflurbiprofen to flurbiprofen was significantly lower in the CYP2C9*1/*3 individuals than in those with CYP2C9*1/*1. These results indicate that the individuals carrying of CYP2C9*3 have significant reduction in flurbiprofen metabolism. The clinical use of this information may allow for more efficient personalized pharmacotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Bae, J.W., H.K. Kim, J.H. Kim, S.I. Yang, M.J. Kim, C.G. Jang, Y.S. Park, and S.Y. Lee. 2005. Allele and genotype frequencies of CYP2C9 in a Korean population. British Journal of Clinical Pharmacology 60: 418–422.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bae, J.W., J.H. Kim, C.I. Choi, M.J. Kim, H.J. Kim, S.A. Byun, Y.S. Chang, C.G. Jang, Y.S. Park, and S.Y. Lee. 2009. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Archives of Pharmacal Research 32: 269–273.

    Article  CAS  PubMed  Google Scholar 

  • Bae, J.W., C.I. Choi, M.J. Kim, D.H. Oh, S.K. Keum, J.I. Park, B.H. Kim, H.K. Bang, S.G. Oh, B.S. Kang, H.J. Park, H.D. Kim, J.H. Ha, H.J. Shin, Y.H. Kim, H.S. Na, M.W. Chung, C.G. Jang, and S.Y. Lee. 2011a. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacologica Sinica 32: 1303–1308.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bae, J.W., C.I. Choi, C.G. Jang, and S.Y. Lee. 2011b. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. British Journal of Clinical Pharmacology 71: 550–555.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Caraco, Y., M. Muszkat, and A.J. Wood. 2001. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11: 587–596.

    Article  CAS  PubMed  Google Scholar 

  • Choi, C.I., M.J. Kim, C.G. Jang, Y.S. Park, J.W. Bae, and S.Y. Lee. 2011. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam. Basic & Clinical Pharmacology & Toxicology 109: 476–480.

    Article  CAS  Google Scholar 

  • Choi, C.I., M.J. Kim, E.K. Chung, H.I. Lee, C.G. Jang, J.W. Bae, and S.Y. Lee. 2012. CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. European Journal of Clinical Pharmacology 68: 149–154.

    Article  CAS  PubMed  Google Scholar 

  • Davies, N.M. 1995. Clinical Pharmacokinetics of flurbiprofen and its enantiomers. Clinical Pharmacokinetics 28: 100–114.

    Article  CAS  PubMed  Google Scholar 

  • Dorado, P., L.J. Beltrán, E. Machín, E.M. Peñas-Lledó, E. Terán, A. Llerena, and CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF. 2012. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender. Pharmacogenomics 13: 1711–1717.

    Article  CAS  PubMed  Google Scholar 

  • Goldstein, J.A. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology 52: 349–355.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Goldstein, J.A., and S.M. de Morais. 1994. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285–299.

    Article  CAS  PubMed  Google Scholar 

  • Kirchheiner, J., J. Brockmoller, I. Meineke, S. Bauer, W. Rohde, C. Meisel, and I. Roots. 2001. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clinical Pharmacology and Therapeutics 71: 286–296.

    Article  Google Scholar 

  • Kirchheiner, J., S. Bauer, I. Meineke, W. Rohde, V. Prang, C. Meisel, I. Roots, and J. Brockmöller. 2002. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12: 101–109.

    Article  CAS  PubMed  Google Scholar 

  • Kirchheiner, J., I. Meineke, N. Steinbach, C. Meisel, I. Roots, and J. Brockmöller. 2003a. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. British Journal of Clinical Pharmacology 55: 51–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kirchheiner, J., E. Störmer, C. Meisel, N. Steinbach, I. Roots, and J. Brockmöller. 2003b. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 13: 473–480.

    Article  CAS  PubMed  Google Scholar 

  • Lee, C.R., J.A. Goldstein, and J.A. Pieper. 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12: 251–263.

    Article  CAS  PubMed  Google Scholar 

  • Lee, C.R., J.A. Pieper, R.F. Frye, A.L. Hinderliter, J.A. Blaisdell, and J.A. Goldstein. 2003a. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. Journal of Clininical Pharmacology 43: 84–91.

    Article  CAS  Google Scholar 

  • Lee, C.R., J.A. Pieper, R.F. Frye, A.L. Hinderliter, J.A. Blaisdell, and J.A. Goldstein. 2003b. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. European Journal of Clinical Pharmacology 58: 791–794.

    CAS  PubMed  Google Scholar 

  • Lee, H.I., J.W. Bae, C.I. Choi, Y.J. Lee, J.Y. Byeon, C.G. Jang, and S.Y. Lee. 2014a. Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenetics and Genomics 24: 113–117.

    Article  CAS  PubMed  Google Scholar 

  • Lee, H.I., C.I. Choi, J.Y. Byeon, J.E. Lee, S.Y. Park, Y.H. Kim, S.H. Kim, Y.J. Lee, C.G. Jang, and S.Y. Lee. 2014b. Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography–tandem mass spectrometry for clinical application. Journal of Chromatography B 971: 58–63.

    Article  CAS  Google Scholar 

  • Li, Z., G. Wang, L.S. Wang, W. Zhang, Z.R. Tan, L. Fan, B.L. Chen, Q. Li, J. Liu, J.H. Tu, D.L. Hu, Z.Q. Liu, and H.H. Zhou. 2009. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 39: 788–793.

    Article  CAS  PubMed  Google Scholar 

  • Llerena, A., M. Alvarez, P. Dorado, I. González, E. Peñas-LLedó, B. Pérez, J. Cobaleda, and L.R. Calzadilla. 2014. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Pharmacogenomics Journal 14: 229–234.

    Article  CAS  PubMed  Google Scholar 

  • Lundblad, M.S., S. Ohlsson, P. Johansson, P. Lafolie, and E. Eliasson. 2006. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clinical Pharmacology and Therapeutics 79: 287–288.

    Article  CAS  PubMed  Google Scholar 

  • Mizutani, T. 2003. PM frequencies of major CYPs in Asians and Caucasians. Drug Metabolism Reviews 35: 99–106.

    Article  CAS  PubMed  Google Scholar 

  • Morin, S., M.A. Loriot, J.M. Poirier, L. Tenneze, P.H. Beaune, C. Funck-Brentano, P. Jaillon, and L. Becquemont. 2001. Is diclofenac a valuable CYP2C9 probe in human? European Journal of Clinical Pharmacology 56: 793–797.

    Article  CAS  PubMed  Google Scholar 

  • Nelson, D.R., L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus, and D.W. Nebert. 1996. P450 superfamily: Update on new sequences, gene mapping accession numbers and nomenclature. Pharmacogenetics 6: 1–4.

    Article  CAS  PubMed  Google Scholar 

  • Prieto-Pérez, R., D. Ochoa, T. Cabaleiro, M. Román, S.D. Sánchez-Rojas, M. Talegón, and F. Abad-Santos. 2013. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. Journal of Clinical Pharmacology 53: 1261–1267.

    Article  PubMed  Google Scholar 

  • Rendic, S., and F.J. Di Carlo. 1997. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews 29: 413–580.

    Article  CAS  PubMed  Google Scholar 

  • Risdall, P.C., S.S. Adams, E.L. Crampton, and B. Marchant. 1978. The disposition and metabolism of flurbiprofen in several species including men. Xenobiotica 8: 691–703.

    Article  CAS  PubMed  Google Scholar 

  • Shimada, T., H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270: 414–423.

    CAS  PubMed  Google Scholar 

  • Shimamoto, J., I. Ieiri, A. Urae, M. Kimura, S. Irie, T. Kubota, K. Chiba, T. Ishizaki, K. Otsubo, and S. Higuchi. 2000. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. European Journal of Clinical Pharmacology 56: 65–68.

    Article  CAS  PubMed  Google Scholar 

  • Shon, J.H., Y.R. Yoon, K.A. Kim, Y.C. Lim, K.J. Lee, J.Y. Park, I.J. Cha, D.A. Flockhart, and J.G. Shin. 2002. Effect of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12: 111–119.

    Article  CAS  PubMed  Google Scholar 

  • Stempak, D., B.L. Bukaveckas, M. Linder, G. Koren, and S. Baruchel. 2005. Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clinical Pharmacology and Therapeutics 78: 309–310.

    Article  CAS  PubMed  Google Scholar 

  • Thakkar, A.N., S.R. Bendkhale, S.R. Taur, N.J. Gogtay, and U.M. Thatte. 2012. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients. Neurology India 60: 577–580.

    Article  PubMed  Google Scholar 

  • Tracy, T.S., B.W. Rosenbluth, S.A. Wrighton, F.J. Gonzalez, and K.R. Korzekwa. 1995. Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen. Biochemical Pharmacology 49: 1269–1275.

    Article  CAS  PubMed  Google Scholar 

  • Varshney, E., N. Saha, M. Tandon, V. Shrivastava, and S. Ali. 2013. Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region. European Journal of Drug Metabolism and Pharmacokinetics 38: 275–282.

    Article  CAS  PubMed  Google Scholar 

  • Wang, L., S.H. Bao, P.P. Pan, M.M. Xia, M.C. Chen, B.Q. Liang, D.P. Dai, J.P. Cai, and G.X. Hu. 2014. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Development and Industrial Pharmacy. doi:10.3109/03639045.2014.950274.

    Google Scholar 

  • Xie, H.G., R.B. Kim, A.J. Wood, and C.M. Stein. 2001. Molecular basis of ethnic differences in drug disposition and response. Annual Review of Pharmacology and Toxicology 4: 815–850.

    Article  Google Scholar 

  • Yamazaki, H., K. Inoue, K. Chiba, N. Ozawa, T. Kawai, Y. Suzuki, J.A. Goldstein, F.P. Guengerich, and T. Shimada. 1998. Comparative studies on the catalytic roles of cytochrome P4502C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology 56: 243–251.

    Article  CAS  PubMed  Google Scholar 

  • Yasar, U., E. Eliasson, C. Forslund-Bergengren, G. Tybring, M. Gadd, F. Sjoqvist, and M.L. Dahl. 2001. The role genotype in the metabolism of diclofenac in vivo and in vitro. European Journal of Clinical Pharmacology 57: 729–735.

    Article  CAS  PubMed  Google Scholar 

  • Yasar, U., C. Forslund-Bergengren, G. Tybring, P. Dorado, A. Llerena, F. Sjoqvist, E. Eliasson, and M.L. Dahl. 2002. Pharmacokinetics of losartan and its metabolites E-3174 in relation to the CYP2C9 genotype. Clinical Pharmacology and Therapeutics 71: 89–98.

    Article  CAS  PubMed  Google Scholar 

  • Zhou, S.F., J.P. Liu, and B. Chowbay. 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41: 89–295.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. School of Pharmacy, Sungkyunkwan University, Suwon, 440-746, Republic of Korea

      Yun-Jeong Lee, Ji-Yeong Byeon, Young-Hoon Kim, Se-Hyung Kim, Choon-Gon Jang, Jeongmi Lee & Seok-Yong Lee

    2. College of Pharmacy, Dankook University, Cheonan, 330-714, Republic of Korea

      Yun-Jeong Lee

    3. College of Pharmacy, Dongguk University-Seoul, Goyang, 410-820, Republic of Korea

      Chang-Ik Choi

    4. College of Pharmacy, Keimyung University, Daegu, 704-701, Republic of Korea

      Jung-Woo Bae

    5. College of Pharmacy, Chung-Ang University, Seoul, 156-756, Republic of Korea

      Uy-Dong Sohn

    Authors
    1. Yun-Jeong Lee
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ji-Yeong Byeon
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Young-Hoon Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Se-Hyung Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Chang-Ik Choi
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Jung-Woo Bae
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Uy-Dong Sohn
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Choon-Gon Jang
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Jeongmi Lee
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Seok-Yong Lee
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Seok-Yong Lee.

    Additional information

    Yun-Jeong Lee and Ji-Yeong Byeon have contributed equally to this study.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Lee, YJ., Byeon, JY., Kim, YH. et al. Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Arch. Pharm. Res. 38, 1232–1237 (2015). https://doi.org/10.1007/s12272-015-0580-0

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12272-015-0580-0

    Keywords

    Search

    Navigation